A randomised, placebo-controlled trial comparing the effects of tapentadol and oxycodone on gastrointestinal and colonic transit in healthy humans

Alimentary Pharmacology and Therapeutics

Volumn 35, Issue 9, 2012, Pages 1088-1096

  Jeong, I D ^a   Camilleri, M ^a   Shin, A ^a   Iturrino, J ^a   Boldingh, A ^a   Busciglio, I ^a   Burton, D ^a   Ryks, M ^a   Rhoten, D ^a   Zinsmeister, A R ^b  

^a MAYO CLINIC   (United States)

^b Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OXYCODONE; PLACEBO; TAPENTADOL;

ACUTE DRUG ADMINISTRATION; ADULT; AGED; ARTICLE; BODY MASS; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG RELEASE; EVENING DOSAGE; FEMALE; GASTROINTESTINAL TRANSIT; HUMAN; HUMAN EXPERIMENT; INTESTINE TRANSIT TIME; MALE; NAUSEA; NORMAL HUMAN; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; STOMACH EMPTYING; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING;

ADULT; ANALGESICS, OPIOID; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL TRANSIT; HUMANS; MALE; NAUSEA; OXYCODONE; PHENOLS; RECEPTORS, OPIOID, MU;

EID: 84875744900     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2012.05040.x     Document Type: Article

References (37)

1. Kaufman PN, Krevsky B, Malmud LS, et al. Role of opiate receptors in the regulation of colonic transit. Gastroenterology 1988; 94: 1351-6.
2. Maurer AH, Krevsky B, Knight LC, Brown K. Opioid and opioid-like drug effects on whole-gut transit measured by scintigraphy. J Nucl Med 1996; 37: 818-22.
3. Löwenstein O, Leyendecker P, Lux EA, et al. Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials. BMC Clin Pharmacol 2010; 10: 12-20.
4. Tzschentke TM, Christoph T, Kögel B, et al. (1R,2R)-3-(3- dimethylamino-1- ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel l-opioid receptor agonist/ norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Experiment Ther 2007; 323: 265-76.
5. Schroder W, Tzschentke TM, Terlinden R, et al. Synergistic interaction between the two mechanisms of action of tapentadol in analgesia. J Pharmacol Exp Ther 2011; 337: 312-20.
6. Stegmann JU, Weber H, Steup A, Okamoto A, Upmalis D, Daniels S. The efficacy and tolerability of multiple-dose tapentadol immediate release for the relief of acute pain following orthopedic [bunionectomy] surgery. Curr Med Res Opin 2008; 24: 3185-96.
7. Hartrick C, Van Hove I, Stegmann J, Oh C, Upmalis D. Efficacy and tolerability of tapentadol immediate rlease and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active and placebo-controlled study. Clin Ther 2009; 31: 260-71.
8. Kleinert R, Lange C, Steup A, Black P, Goldberg J, Desjardins P. Single dose analgesic efficacy of tapentadol in postsurgical dental pain: the results of a randomized, double-blind, placebocontrolled study. Anesth Analg 2008; 107: 2048-55.
9. Tzschentke TM, Jahnel U, Kogel B, et al. Tapentadol hydrochloride: a nextgeneration, centrally acting analgesic with two mechanisms of action in a single molecule. Drugs Today (Barc) 2009; 45: 483-96.
10. Terlinden R, Ossig J, Fliegert F, Lange C, Göhler K. Absorption, metabolism, and excretion of 14C-labeled tapentadol HCl in healthy male subjects. Eur J Drug Metab Pharmacokinet 2007; 32: 163-9.
11. Lalovic B, Kharasch E, Hoffer C, Risler L, Liu-Chen LY, Shen DD. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther 2006; 79: 461-79.
12. Burton DD, Camilleri M, Mullan BP, Forstrom LA, Hung JC. Colonic transit scintigraphy labeled activated charcoal compared with ion exchange pellets. J Nucl Med 1997; 38: 1807-10.
13. Camilleri M, Colemont LJ, Phillips SF, et al. Human gastric emptying and colonic filling of solids characterized by a new method. Am J Physiol 1989; 257: G284-90.
14. Camilleri M, Zinsmeister AR. Towards a relatively inexpensive, noninvasive, accurate test for colonic motility disorders. Gastroenterology 1992; 103: 36-42.
15. Camilleri M, Zinsmeister AR, Greydanus MP, Brown ML, Proano M. Towards a less costly but accurate test of gastric emptying and small bowel transit. Dig Dis Sci 1991; 36: 609-15.
16. Cremonini F, Mullan BP, Camilleri M, Burton DD, Rank MR. Performance characteristics of scintigraphic transit measurements for studies of experimental therapies. Aliment Pharmacol Ther 2002; 16: 1781-90.
17. Deiteren A, Camilleri M, Bharucha AE, et al. Performance characteristics of scintigraphic colon transit measurement in health and irritable bowel syndrome and relationship to bowel functions. Neurogastroenterol Motil 2010; 22: 415-23.
18. Manabe N, Wong BS, Camilleri M, Burton D, McKinzie S, Zinsmeister AR. Lower functional gastrointestinal disorders: evidence of abnormal colonic transit in a 287 patient cohort. Neurogastroenterol Motil 2010; 22: 293.
19. Gonenne J, Camilleri M, Ferber I, et al. Effect of alvimopan and codeine on gastrointestinal transit: a randomized controlled study. Clin Gastroenterol Hepatol 2005; 3: 784-91.
20. ParkM-I, Ferber I, CamilleriM, et al. Effect of atilmotin on gastrointestinal transit in healthy subjects: a randomized, placebo-controlled study. NeurogastroenterolMotil 2006; 18: 28-36.
21. Esfandyari T, Camilleri M, Ferber I, Burton D, Baxter K, Zinsmeister AR. Effect of a cannabinoid agonist on gastrointestinal transit and postprandial satiation in healthy human subjects: a randomized, placebo-controlled study. Neurogastroenterol Motil 2006; 18: 831-8.
22. Camilleri M, Vazquez-Roque MI, Burton D, et al. Pharmacodynamic effects of a novel prokinetic 5-HT4 receptor agonist, ATI-7505, in humans. Neurogastroenterol Motil 2007; 19: 30-8.
23. Daniels S, Upmalis D, Okamoto A, Lange C, Haeussler J. A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain. Curr Med Res Opin 2009; 25: 765-76.
24. Hale M, Upmalis D, Okamoto A, Lange C, Rauschkolb C. Long-term safety and tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee: a randomized, double-blind study. Curr Med Res Opin 2009; 25: 1095-104.
25. Afilalo M, Etropolski MS, Kuperwasser B, et al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. Clin Drug Investig 2010; 30: 489-505.
26. Buynak R, Shapiro DY, Okamoto A, et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study. Expert Opin Pharmacother 2010; 11: 1787-804.
27. Lange B, Kuperwasser B, Okamoto A, et al. Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Adv Ther 2010; 27: 381-99.
28. Daniels S, Casson E, Stegmann JU, et al. A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain. Curr Med Res Opin 2009; 25: 1551-61.
29. Schwartz S, Etropolski M, Shapiro DY, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebocontrolled trial. Curr Med Res Opin 2011; 27: 151-62.
30. Vorsanger G, Xiang J, Okamoto A, Upmalis D, Moskovitz B. Evaluation of study discontinuations with tapentadol immediate release and oxycodone immediate release in patients with low back or osteoarthritis pain. J Opioid Manag 2010; 6: 169-79.
31. Wild JE, Grond S, Kuperwasser B, et al. Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract 2010; 10: 416-27.
32. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic noncancer pain: systematic review of efficacy and safety. Pain 2004; 112: 372-80.
33. Vorsanger G, Xiang J, Biondi D, et al. Post hoc analyses of data from a 90-day clinical trial evaluating the tolerability and efficacy of tapentadol immediate release and oxycodone immediate release for the relief of moderate to severe pain in elderly and nonelderly patients. Pain Res Manag 2011; 16: 245-51.
34. Barrow L, Steed KP, Spiller RC, et al. Quantitative, noninvasive assessment of antidiarrheal actions of codeine using an experimental model of diarrhea in man. Dig Dis Sci 1993; 38: 996-1003.
35. Ross GR, Gabra BH, Dewey WL, Akbarali HI. Morphine tolerance in the mouse ileum and colon. J Pharmacol Exp Ther 2008; 327: 561-72.
36. Bredenoord AJ, Chial HJ, Camilleri M, Mullan BP, Murray JA. Gastric accommodation and emptying in evaluation of patients with upper gastrointestinal symptoms. Clin Gastroenterol Hepatol 2003; 1: 264-72.
37. Camilleri M. Opioid-induced constipation: challenges and therapeutic opportunities. Am J Gastroenterol 2011; 106: 835-42.